Cargando…

Is extended resistance to the historical antiretroviral drugs & drug classes still a risk factor for HIV progression?

Detalles Bibliográficos
Autores principales:	Zaccarelli, M, Lorenzini, P, Marconi, P, Forbici, F, Gori, C, Sette, P, Ceccherini-Silberstein, F, Narciso, P, Perno, CF, Antinori, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112914/ http://dx.doi.org/10.1186/1758-2652-13-S4-P138

Ejemplares similares

No significant association between patient self-reported non-adherence to antiretrovirals and HIV-tropism: a preliminary analysis
por: Ammassari, A, et al.
Publicado: (2012)

A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naïve Patients Starting a First-Line HAART
por: Armenia, Daniele, et al.
Publicado: (2014)

Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs
por: Alteri, Claudia, et al.
Publicado: (2009)

Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection
por: Mondi, Annalisa, et al.
Publicado: (2022)

Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs
por: Berno, Giulia, et al.
Publicado: (2014)

Resistance to new antiretrovirals (ETV, anti-integrases, entry inhibitors)
por: Ceccherini-Silberstein, Francesca
Publicado: (2010)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study
por: Latini, Alessandra, et al.
Publicado: (2016)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
por: Zaccarelli, Mauro, et al.
Publicado: (2014)

HIV-1 drug resistance in recently HIV-infected pregnant mother’s naïve to antiretroviral therapy in Dodoma urban, Tanzania
por: Vairo, Francesco, et al.
Publicado: (2013)

The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing
por: Svicher, Valentina, et al.
Publicado: (2013)

Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy
por: Fabeni, Lavinia, et al.
Publicado: (2015)

Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study
por: Prosperi, Mattia CF, et al.
Publicado: (2012)

Drug Users in Amsterdam: Are They Still at Risk for HIV?
por: van der Knaap, Nienke, et al.
Publicado: (2013)

HIV DNA Sequencing to Detect Archived Antiretroviral Drug Resistance
por: Geretti, Anna Maria, et al.
Publicado: (2022)

Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003–2012 decade in Italy
por: Franzetti, Marco, et al.
Publicado: (2014)

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice
por: Costarelli, Silvia, et al.
Publicado: (2016)

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients
por: Berno, Giulia, et al.
Publicado: (2014)

The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
por: Amendola, Alessandra, et al.
Publicado: (2020)

Correction: The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
por: Amendola, Alessandra, et al.
Publicado: (2020)

Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy
por: Saracino, Annalisa, et al.
Publicado: (2018)

Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis
por: Girardi, Enrico, et al.
Publicado: (2012)

Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals
por: Mukonzo, Jackson, et al.
Publicado: (2019)

Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant?
por: Pitman, Stuart K., et al.
Publicado: (2019)

Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120(V3 )signatures in the regulation of Co-Receptor usage
por: Dimonte, Salvatore, et al.
Publicado: (2011)

Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals
por: Rozera, Gabriella, et al.
Publicado: (2017)

Antiretroviral drug exposure in lymph nodes is heterogeneous and drug dependent
por: Rosen, Elias P., et al.
Publicado: (2022)

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
por: Mondi, Annalisa, et al.
Publicado: (2019)

HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon
por: Takou, Desire, et al.
Publicado: (2019)

HIV-1 Gag gene mutations, treatment response and drug resistance to protease inhibitors: A systematic review and meta-analysis protocol
por: Nka, Alex Durand, et al.
Publicado: (2021)

Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use
por: Le, Thuy, et al.
Publicado: (2009)

A “Sodium Drug” for Generalized Epilepsy? A Mystery That Still Needs to be Solved
por: Szaflarski, Jerzy P.
Publicado: (2021)

Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy
por: Fabeni, Lavinia, et al.
Publicado: (2020)

Historical Perspective on Adding Drugs to Medicare
por: Santangelo, Mark
Publicado: (2005)

Methadone, Buprenorphine, and Street Drug Interactions with Antiretroviral Medications
por: Gruber, Valerie A., et al.
Publicado: (2010)

Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy
por: Meini, Genny, et al.
Publicado: (2014)

Antiretroviral drug–drug interactions: A comparison of online drug interaction databases
por: Drwiega, Emily N., et al.
Publicado: (2022)

Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs
por: Petrykiv, S., et al.
Publicado: (2022)

Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance
por: Charpentier, Charlotte, et al.
Publicado: (2023)

Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis
por: Duwal, Sulav, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mrgeet04ot333bvbh5pl35m1q0